Unlocking the potential of mesoporous silica nanoparticles in breast cancer treatment
Breast cancer is the most common cancer among women and is typically managed through
surgery, radiation therapy, and chemotherapy. However, chemotherapy drugs often lack …
surgery, radiation therapy, and chemotherapy. However, chemotherapy drugs often lack …
[HTML][HTML] Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue
Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in
women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for …
women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for …
Recent advances in nanoparticle-based cancer drug and gene delivery
Effective and safe delivery of anticancer agents is among the major challenges in cancer
therapy. The majority of anticancer agents are toxic to normal cells, have poor bioavailability …
therapy. The majority of anticancer agents are toxic to normal cells, have poor bioavailability …
Nanomedicine in treatment of breast cancer–A challenge to conventional therapy
M Afzal, KS Alharbi, NK Alruwaili, FA Al-Abassi… - Seminars in cancer …, 2021 - Elsevier
Amongst the various types of cancer, breast cancer is a highly heterogeneous disease and
known as the leading cause of death among women globally. The extensive interdisciplinary …
known as the leading cause of death among women globally. The extensive interdisciplinary …
Nanocarriers based on vitamin E-TPGS: Design principle and molecular insights into improving the efficacy of anticancer drugs
Abstract α-Tocopheryl polyethylene glycol succinate (vitamin E-TPGS or TPGS) is a nonionic
amphiphile synthesized by the esterification of vitamin E succinate. It has been categorized …
amphiphile synthesized by the esterification of vitamin E succinate. It has been categorized …
Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy
S Tan, C Zou, W Zhang, M Yin, X Gao, Q Tang - Drug Delivery, 2017 - Taylor & Francis
Cancer remains an obstacle to be surmounted by humans. As an FDA-approved
biocompatible drug excipient, d-α-tocopheryl polyethylene glycol succinate (TPGS) has …
biocompatible drug excipient, d-α-tocopheryl polyethylene glycol succinate (TPGS) has …
Partner-specific drug repositioning approach based on graph convolutional network
Drug repositioning identifies novel therapeutic potentials for existing drugs and is
considered an attractive approach due to the opportunity for reduced development timelines …
considered an attractive approach due to the opportunity for reduced development timelines …
Tumor microenvironment stimuli-responsive lipid-drug conjugates for cancer treatment
Lipid drug conjugates (LDCs) have attracted considerable attention in the fields of drug
delivery and pharmacology due to their ability to target specific cells, increase drug …
delivery and pharmacology due to their ability to target specific cells, increase drug …
Recent advances of D-α-tocopherol polyethylene glycol 1000 succinate based stimuli-responsive nanomedicine for cancer treatment
Y Guan, L Wang, B Wang, M Ding, Y Bao, S Tan - Current medical science, 2020 - Springer
D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) is a pharmaceutical excipient
approved by Chinese NMPA and FDA of USA. It's widely applied as a multifunctional drug …
approved by Chinese NMPA and FDA of USA. It's widely applied as a multifunctional drug …
Spatiotemporally controllable diphtheria toxin expression using a light-switchable transgene system combining multifunctional nanoparticle delivery system for …
M He, Y Wang, X Chen, Y Zhao, K Lou, Y Wang… - Journal of Controlled …, 2020 - Elsevier
Gene therapy with external gene insertion (eg a suicide gene) and expression specifically in
mutated tumor cells has shown to be a promising strategy in treatment of tumors. However …
mutated tumor cells has shown to be a promising strategy in treatment of tumors. However …